304 CHAPTER 4.1 Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) G 2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 63 6.3% 2 0% 28 7.1% 4 50.0% 29 0% C 5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation 60 31.7% 9 44.4% 43 23.3% 2 100% 6 50.0% L 2. Use of regular (as distinct from PRN) opioids without concomitant laxative 56 12.5% 20 0% 19 10.5% 0 N/A 17 29.4% C 6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease . 51 17.6% 3 0% 42 14.3% 2 100% 4 25.0% B 7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure 48 25.0% 3 33.3% 33 12.1% 4 25.0% 8 75.0% L 1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain 47 10.6% 8 0.0% 32 12.5% 1 0% 6 16.7% B 5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias 46 32.6% 9 11.1% 25 36.0% 6 66.7% 6 16.7%
RkJQdWJsaXNoZXIy MTk4NDMw